These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Guidelines of treatment for non-bleeding peptic ulcer disease]. Cheung DY; Jung HY; Song HJ; Jung SW; Jung HC; ; Korean J Gastroenterol; 2009 Nov; 54(5):285-97. PubMed ID: 19934610 [TBL] [Abstract][Full Text] [Related]
46. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Nishikawa K; Sugiyama T; Kato M; Ishizuka J; Komatsu Y; Kagaya H; Katagiri M; Nishikawa S; Hokari K; Takeda H; Asaka M Eur J Gastroenterol Hepatol; 2000 Jun; 12(6):635-40. PubMed ID: 10912481 [TBL] [Abstract][Full Text] [Related]
47. Peptic ulcer disease: clinically relevant causes and treatments. Mynatt RP; Davis GA; Romanelli F Orthopedics; 2009 Feb; 32(2):104. PubMed ID: 19301796 [TBL] [Abstract][Full Text] [Related]
48. Review article: the effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Laine L Aliment Pharmacol Ther; 2002 Mar; 16 Suppl 1():34-9. PubMed ID: 11849126 [TBL] [Abstract][Full Text] [Related]
49. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. Sugano K; Kinoshita Y; Miwa H; Takeuchi T; Aliment Pharmacol Ther; 2012 Jul; 36(2):115-25. PubMed ID: 22591121 [TBL] [Abstract][Full Text] [Related]
50. [Healing peptic ulcer disease with therapy of Helicobacter pylori infection--an overview]. Leodolter A; Peitz U; Malfertheiner P Wien Med Wochenschr; 2001; 151(13-14):300-8. PubMed ID: 11582994 [TBL] [Abstract][Full Text] [Related]
51. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios]. Limmer S; Ittel TH; Wietholtz H Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426 [TBL] [Abstract][Full Text] [Related]
52. Current indications for acid suppressants in Helicobacter pylori -negative ulcer disease. Howden CW; Leontiadis GI Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):401-12. PubMed ID: 11403535 [TBL] [Abstract][Full Text] [Related]
53. Peptic ulcer disease in the 1990s: an Asian perspective. Fock KM J Gastroenterol Hepatol; 1997 Jun; 12(6):S23-8. PubMed ID: 9195408 [TBL] [Abstract][Full Text] [Related]
54. The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Barkin J Am J Med; 1998 Nov; 105(5A):22S-27S. PubMed ID: 9855172 [TBL] [Abstract][Full Text] [Related]
56. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Labenz J; Blum AL; Bolten WW; Dragosics B; Rösch W; Stolte M; Koelz HR Gut; 2002 Sep; 51(3):329-35. PubMed ID: 12171952 [TBL] [Abstract][Full Text] [Related]
57. Peptic ulcer: a problem almost solved. Baron JH J R Coll Physicians Lond; 1997; 31(5):512-20. PubMed ID: 9429188 [No Abstract] [Full Text] [Related]
58. Frequency of NSAID induced peptic ulcer disease. Hamid S; Yakoob J; Jafri W; Islam S; Abid S; Islam M J Pak Med Assoc; 2006 May; 56(5):218-22. PubMed ID: 16767948 [TBL] [Abstract][Full Text] [Related]